Summit Partners Public Asset Management, LLC Madrigal Pharmaceuticals, Inc. Transaction History

Summit Partners Public Asset Management, LLC

$2.79 Billion
Q3 2024

1 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2023 Feb 14, 2024	BUY	$120.4 - $237.13 $9.91 Million - $19.5 Million	82,287 New	82,287 $19 Million

Others Institutions Holding MDGL

# of Institutions

297

Shares Held

22M

Call Options Held

819K

Put Options Held

640K

Janus Henderson Group PLC London, X0

2.48M
Shares

$778 Million
0.28% of portfolio
John Paulson Paulson & Co. Inc. | New York, Ny

2.04M
Shares

$641 Million
29.57% of portfolio
Avoro Capital Advisors LLC New York, NY

2.03M
Shares

$637 Million
6.48% of portfolio
Rtw Investments, LP New York, NY

1.99M
Shares

$626 Million
6.74% of portfolio
Baker Bros. Advisors LP New York, NY

1.97M
Shares

$620 Million
4.49% of portfolio

View Full List

About MADRIGAL PHARMACEUTICALS, INC.

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.37B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

More about MDGL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Summit Partners Public Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Summit Partners Public Asset Management, LLC with notifications on news.

Account